Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Smart technology for patient-centered care in pulmonary embolism

Official title: Smart Technology Facilitated Patient-centered Care for Patients With Pulmonary Thromboembolism:A Multicenter, Randomized Controlled Trial

Run by Navy General Hospital, Beijing · NCT06382038 · Data updated 2026-11-12

A smartphone-based program using wearable tech and AI will help people with pulmonary embolism manage their health and see if it improves long-term outcomes.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment2972 (estimated)
SponsorNavy General Hospital, Beijing
Academic / other
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedAugust 20, 2026
Main results expectedSeptember 30, 2028
Study endsSeptember 30, 2029
Registry record updatedSeptember 9, 2026
Trial IDNCT06382038 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 years or older with imaging-confirmed pulmonary embolism, either newly diagnosed during the current hospitalization or with residual thrombus from a prior event, who can use smartphones or tablets and consent to participate.

Probably not a fit

Patients unable to use smart devices or with conditions preventing independent living may not benefit from this digital intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial tests a mobile health application designed for patients with pulmonary embolism, incorporating wearable and digital tools to support pre-warning, decision support, education, and ongoing care. It focuses on long-term outcomes and aims to inform best practices for managing PTE through technology-assisted, patient-centered care. Participants are adults with imaging-confirmed PTE who can use smart devices, and the intervention is delivered through the mVTEA app. The study is sponsor-led by Navy General Hospital in Beijing, with enrollment at a single center in Beijing. Results could help determine whether digital health approaches can enhance access to high-quality resources and improve thrombosis management.

Why it matters

Potential benefit: If successful, patients may experience better long-term management and outcomes through continuous monitoring and education enabled by mobile technology.

How similar studies have gone: Digital health tools have shown mixed results in thrombosis care, with some studies indicating potential benefits in management and education, while broader, definitive evidence remains evolving.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Inpatients aged ≥18 years;
* PTE confirmed through imaging examinations, meeting at least one of the following criteria: a.Newly diagnosed PTE during the current hospitalization; b. Prior PTE with imaging evidence of residual thrombus.
* Signed informed consent.

Exclusion Criteria:

* Previous PTE combined with CTEPH;
* Mental retardation or a combination of other serious illnesses that make them incapable of living on their own;
* Inability to use smartphones, computer tablets and other smart devices;
* Being pregnant or breastfeeding;
* Have participated in similar trials or are undergoing other clinical trials.

Where it's running

  • Sixth Medical Center of Chinese PLA General Hospital
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.